Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-04-19 00:00:00 ET · period of report 2023-04-17 · accession 0000899243-23-011461 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-04-19 | 2023-04-17 | AMLX | Yeramian Patrick D | Chief Medical Off | S - Sale+OE | $30.53 | -49.6K | 208.7K | -19% | -$1.51M |
| DM | 2023-04-19 | 2023-04-17 | AMLX | Yeramian Patrick D | Chief Medical Off | M - OptEx | $0.9895 | +49.6K | 258.0K | +24% | +$49.1K |
| DM | 2023-04-19 | 2023-04-17 | AMLX | Yeramian Patrick D | Chief Medical Off | M - OptEx | $0.00 | -49.6K | 17.6K | -74% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-17 | S | D | 300 | $30.94 | 208,417 | D | — | — | |
| 2 | Common | Common Stock | 2023-04-17 | S | D | 49,279 | $30.53 | 208,717 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2023-04-17 | M | A | 44,861 | $0.37 | 253,278 | D | — | — | |
| 4 | Common | Common Stock | 2023-04-17 | M | A | 4,718 | $6.88 | 257,996 | D | — | — | |
| 5 | Derivative | Stock Option (right to buy) | 2023-04-17 | M | D | 4,718 | $0.00 | 43,534 | D | $6.88 · — to 2031-02-21 | 4,718 Common Stock | (F4) As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023. |
| 6 | Derivative | Stock Option (right to buy) | 2023-04-17 | M | D | 44,861 | $0.00 | 17,605 | D | $0.37 · — to 2029-03-18 | 44,861 Common Stock | (F3) As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023. |